OS Therapies Incorporated (OSTX)
NYSEAMERICAN: OSTX · Real-Time Price · USD
1.880
+0.080 (4.44%)
At close: Jun 26, 2026, 4:00 PM EDT
1.870
-0.010 (-0.53%)
After-hours: Jun 26, 2026, 8:00 PM EDT
OS Therapies Employees
As of December 31, 2025, OS Therapies had 5 total employees, including 4 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
5
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$7,054,763
Market Cap
83.73M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5 | 0 | - |
| Dec 31, 2024 | 5 | 1 | 25.00% |
| Dec 31, 2022 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Heron Therapeutics | 128 |
| Adicet Bio | 102 |
| Cardiff Oncology | 31 |
| Entera Bio | 22 |
| iBio, Inc. | 20 |
| LeonaBio | 19 |
| Rallybio | 14 |
| MAIA Biotechnology | 13 |
OSTX News
- 2 days ago - OS Animal Health Announces Peer-Reviewed Publication of Clinical Trial Data for OST-HER2 Plus Palliative Radiation as Frontline Treatment in Canine Osteosarcoma - Newsfile Corp
- 20 days ago - OS Therapies Achieves Global Regulatory Alignment on Design of Phase 3 Trial of OST-HER2 in Fully Resected, Pulmonary Metastatic Osteosarcoma - Newsfile Corp
- 26 days ago - OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic Osteosarcoma - Newsfile Corp
- 4 weeks ago - OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World - Newsfile Corp
- 4 weeks ago - OS Therapies to Attend Upcoming Medical, Financial and Industry Conferences - Newsfile Corp
- 5 weeks ago - OS Therapies price target lowered to $13 from $14 at Lake Street - TheFly
- 5 weeks ago - OS Therapies Quarterly report: Q1 2026 - Filings
- 5 weeks ago - OS Therapies Earnings release: Q1 2026 - Filings